![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Simeprevir plus sofosbuvir with/without ribavirin in HCV genotype-1 prior null-responder / treatment-naļve patients (COSMOS study): primary endpoint (SVR12) results in patients with METAVIR F3-4 (Cohort 2)
|
|
|
Reported by Jules Levin
EASL 2014 April 9-13 London, UK
Eric Lawitz,1 Reem Ghalib,2 Maribel Rodriguez-Torres,3 Zobair M Younossi,4 Ana Corregidor,5 Mark S Sulkowski,6 Edwin DeJesus,7 Brian Pearlman,8 Mordechai Rabinovitz,9 Norman Gitlin,10 Joseph K Lim,11 Paul J Pockros,12 Bart Fevery,13
Tom Lambrecht,14 Sivi Ouwerkerk-Mahadevan,13 Katleen Callewaert,13 William T Symonds,15 Gaston Picchio,16 Karen Lindsay,17 Maria Beumont-Mauviel,13 Ira M Jacobson18
1The Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, USA; 2Medicine and Gastroenterology and Hepatology, The Liver Institute, Dallas, TX, USA; 3Fundacion de Investigacion, San Juan, Puerto Rico, USA; 4Department of Medicine, Inova Fairfax Hospital, Falls Church, VA, USA; 5Borland-Groover Clinic, Jacksonville, FL, USA; 6Johns Hopkins University School of Medicine, Baltimore, MD, USA; 7Orlando Immunology Center, Orlando, FL, USA; 8Atlanta Medical Center, Atlanta, GA, USA; 9University of Pittsburgh Medical Center, Pittsburgh, PA, USA; 10Atlanta Gastroenterology Association, Atlanta, GA, USA; 11Yale School of Medicine, New Haven, CT, USA; 12Scripps Clinic, La Jolla, CA, USA; 13Janssen Research & Development, Beerse, Belgium; 14Novellas Healthcare, Zellik, Belgium; 15Gilead Sciences Inc, Foster City, CA, USA; 16Janssen Research & Development LLC, Titusville, NJ, USA; 17Formerly of Janssen Research & Development LLC, Titusville, NJ, USA; 18Weill Cornell Medical College, New York, NY, USA
![EASL1.gif](../images/041414/041414-3/EASL1.gif)
![EASL2.gif](../images/041414/041414-3/EASL2.gif)
![EASL3.gif](../images/041414/041414-3/EASL3.gif)
![EASL4.gif](../images/041414/041414-3/EASL4.gif)
![EASL5.gif](../images/041414/041414-3/EASL5.gif)
![EASL6.gif](../images/041414/041414-3/EASL6.gif)
![EASL7.gif](../images/041414/041414-3/EASL7.gif)
![EASL8.gif](../images/041414/041414-3/EASL8.gif)
![EASL9.gif](../images/041414/041414-3/EASL9.gif)
![EASL10.gif](../images/041414/041414-3/EASL10.gif)
![EASL11.gif](../images/041414/041414-3/EASL11.gif)
![EASL12.gif](../images/041414/041414-3/EASL12.gif)
![EASL13.gif](../images/041414/041414-3/EASL13.gif)
![EASL14.gif](../images/041414/041414-3/EASL14.gif)
![EASL15.gif](../images/041414/041414-3/EASL15.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|